Document is current

Article History

Received: 4 April 2022

Revised: 2 May 2022

Accepted: 2 May 2022

First Online: 19 May 2022

Declarations

:

: Dr. Braemswig is a participant in the Berlin Institute of Health-Charité Clinician Scientist Program funded by the Charité – Universitätsmedizin Berlin and the Berlin Institute of Health. Dr. Simonsen reports research grants from Novo Nordisk Foundation and Health Research Foundation of Central Denmark Region. Prof. Scheitz is participant in the BIH-Charité Advanced Clinician Scientist Program funded by the Charité – Universitätsmedizin Berlin and the Berlin Institute of Health. Prof. Fiebach reports personal fees from Abbvie, AC Immune, Artemida, Bioclinica, Biogen, BMS, Brainomix, Cerevast, Daiichi-Sankyo, Eisai, Eli Lilly, Guerbet, Ionis Pharmaceuticals, Julius clinical, jung diagnostics, Merck, Nicolab, and Tau Rx, all outside the submitted work. Prof. Endres received funding from DFG under Germany´s Excellence Strategy – EXC-2049 – 390688087, BMBF, DZNE, DZHK, EU, Corona Foundation, and Fondation Leducq. Prof. Endres reports grants from Bayer and fees paid to the Charité from AstraZeneca, Bayer, Boehringer Ingelheim, BMS, Daiichi Sankyo, Amgen, GSK, Sanofi, Covidien, Novartis, Pfizer, all outside the submitted work. Prof. Lemmens is a senior clinical investigator of FWO Flanders. Dr. Schlemm is a participant in the Berlin Institute of Health-Charité Clinician Scientist Program funded by the Charité – Universitätsmedizin Berlin and the Berlin Institute of Health. Dr. Schlemm reports lecture fees from Daiichi Sankyo, outside of the submitted work. Prof. Nolte is participant of the BIH-Charité Clinical Fellow Program. Prof. Nolte reports lecture fees and/or consultancies from Bayer, Boehringer Ingelheim, BMS, Daiichi Sankyo, Pfizer, Alexion, Abbott and Gore & Ass., all outside the submitted work. All other authors declare that they have no conflict of interest.

: This is an exploratory analysis of the WAKE-UP trial (Efficacy and Safety of MRI-Based Thrombolysis in Wake-Up Stroke, ClinicalTrials.gov: NCT01525290).[] For each study site, the trial was approved by the national or local ethics committee or institutional review board, as described previously [, ]. Patients or their legal representatives provided written informed consent according to national and local regulations with an exception from explicit informed consent in emergency circumstances in some countries [, ].